Читать книгу Biologics, Biosimilars, and Biobetters - Группа авторов - Страница 93

Developed by Genentech, ranibizumab, an injectable, is marketed in the United States by Genentech and by Novartis outside the United States.

Indication: Age‐related macular degeneration

Manufacturer: Roche, Novartis

Global Sales in 2017: US$1.5 billion

Generic name: Ranibizumab

Launch date: 2006